FMP
Johnson & Johnson
JNJ
NYSE
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
156.31 USD
0.4 (0.256%)
Mr. Joaquin Duato
Healthcare
Drug Manufacturers - General
NYSE
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive banda...
0000200406
US4781601046
478160104
One Johnson & Johnson Plaza
732 524 0400
US
138,100
Jan 2, 1943
0000200406
NYSE
Drug Manufacturers -...
Healthcare
478160104
US4781601046
US
156.31
0.48
9.73M
376.68B
-
140.68-169.99
221.51
-
-
-
-
17.37
-
https://www.jnj.com
Rating Distribution
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Gordon Thompson
Apr 15, 2025
Johnson & Johnson (NYSE:JNJ) is a multinational corporation known for its wide range of healthcare products, including pharmaceuticals, medical devices, and consumer health goods. The company competes with other major players in the healthcare industry, such as Pfizer and Merck. On April 15, 2025, JNJ reported impressive financial results, showcasing its strong market position. The company reported earnings per share (EPS) of $2.77, surpassing the estimated $2.58. This result also exceeded the ...
Parth Sanghvi
Apr 15, 2025
Johnson & Johnson (NYSE: JNJ) delivered a solid Q1 performance, surpassing Wall Street expectations for both revenue and profit, as its pharmaceutical arm continues to shine — particularly in oncology. Despite some drag from biosimilar competition and U.S. tariffs, the company lifted its full-year revenue outlook, banking on its growing drug portfolio. Q1 2025 Highlights Revenue: $21.89 billion (+2.4% YoY) Adjusted EPS: $2.77 (vs. $2.59 est.) Innovative Medicines revenue: $13.87 bill...
Alex Lavoie
Apr 11, 2025
Johnson & Johnson (NYSE:JNJ) is a global leader in the healthcare sector, known for its diverse range of products in pharmaceuticals, medical devices, and consumer health. As the company prepares to release its quarterly earnings on April 15, 2025, Wall Street analysts predict an earnings per share (EPS) of $2.59 and revenue of approximately $21.6 billion. Analysts are closely examining Johnson & Johnson's financial metrics to gain a deeper understanding of its performance. The company's price-...
Davit Kirakosyan
Apr 4, 2025
UBS reaffirmed its Buy rating on Johnson & Johnson (NYSE:JNJ) and maintained a $180 price target, but highlighted short-term volatility risks following the latest legal setback in the company’s ongoing talc litigation saga. A recent court decision marked the third rejection of J&J’s attempt to use bankruptcy proceedings as a pathway to resolve current and future talc-related lawsuits — despite reportedly having over 75% support from claimants. UBS notes that this has significantly dented investo...
Davit Kirakosyan
Apr 1, 2025
TD Cowen reaffirmed its Buy rating and $185 price target on Johnson & Johnson (NYSE:JNJ) following news that a federal judge rejected the company's latest bankruptcy-based proposal to settle its talc-related lawsuits, which pushed the stock price down more than 5% intra-day today. According to the report, the court took issue with the voting process tied to the proposed trust structure, which was designed to handle claims outside of traditional litigation channels. While Johnson & Johnson has no...
Andrew Wynn
Jan 24, 2025
Johnson & Johnson (NYSE:JNJ) is a well-known multinational corporation involved in the development and sale of healthcare products. The company operates in three main segments: Consumer Health, Pharmaceutical, and Medical Devices. It faces competition from other major healthcare companies like Pfizer and Merck. Recently, J&J has come under scrutiny due to an investigation by Pomerantz LLP regarding potential securities fraud. The investigation by Pomerantz LLP follows J&J's decision to pause th...
Stuart Mooney
Jan 23, 2025
Johnson & Johnson (NYSE:JNJ) is a global healthcare company known for its pharmaceuticals, medical devices, and consumer health products. The company competes with other major players like Pfizer and Merck. On January 22, 2025, JNJ reported earnings per share (EPS) of $2.04, surpassing the estimated $1.99. The company also reported revenue of $22.52 billion, exceeding the estimated $22.45 billion. Despite these positive earnings, JNJ's stock experienced a decline. This dip followed the release ...
Davit Kirakosyan
Jan 22, 2025
Johnson & Johnson (NYSE:JNJ) delivered fourth-quarter results that surpassed Wall Street expectations, driven by robust demand for its cancer treatments and strategic acquisitions. The pharmaceutical giant also provided an upbeat forecast for 2025, projecting full-year sales of $90.9 billion to $91.7 billion and adjusted earnings per share of $10.75 to $10.95, both above analyst estimates. Revenue for the quarter climbed 5.3% year-over-year to $22.52 billion, bolstered by a remarkable 19% increa...